Amicus Therapeutics, Inc. FOLD
We take great care to ensure that the data presented and summarized in this overview for AMICUS THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FOLD
View all-
Vanguard Group Inc Valley Forge, PA29.3MShares$280 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA28.5MShares$272 Million0.05% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$233 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY24.2MShares$232 Million7.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$222 Million3.18% of portfolio
-
William Blair Investment Management, LLC Chicago, IL15.6MShares$149 Million0.38% of portfolio
-
State Street Corp Boston, MA10.4MShares$99.1 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V89.44MShares$90.3 Million0.14% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il8.24MShares$78.8 Million0.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA7.66MShares$73.3 Million11.53% of portfolio
Latest Institutional Activity in FOLD
Top Purchases
Top Sells
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions at FOLD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Bradley L Campbell President and CEO |
SELL
Open market or private sale
|
Direct |
400
-0.03%
|
$4,000
$10.0 P/Share
|
|
Feb 19
2025
|
Bradley L Campbell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.03%
|
$3,600
$9.03 P/Share
|
|
Feb 11
2025
|
Samantha Prout Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,500
-10.98%
|
$121,500
$9.57 P/Share
|
|
Feb 11
2025
|
Samantha Prout Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,416
+18.23%
|
-
|
|
Feb 11
2025
|
Bradley L Campbell President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
70,711
-5.79%
|
$636,399
$9.57 P/Share
|
|
Feb 11
2025
|
Bradley L Campbell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
137,075
+10.1%
|
-
|
|
Feb 11
2025
|
David Michael Clark Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,593
-5.58%
|
$185,337
$9.57 P/Share
|
|
Feb 11
2025
|
David Michael Clark Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,338
+12.43%
|
-
|
|
Feb 11
2025
|
Jeff Castelli Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,724
-4.65%
|
$204,516
$9.57 P/Share
|
|
Feb 11
2025
|
Jeff Castelli Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,338
+9.68%
|
-
|
|
Feb 11
2025
|
Ellen Rosenberg Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,584
-5.33%
|
$257,256
$9.57 P/Share
|
|
Feb 11
2025
|
Ellen Rosenberg Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,800
+10.78%
|
-
|
|
Jan 04
2025
|
David Michael Clark Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,692
-0.84%
|
$24,228
$9.41 P/Share
|
|
Jan 04
2025
|
Samantha Prout Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,297
-1.34%
|
$11,673
$9.41 P/Share
|
|
Jan 04
2025
|
Ellen Rosenberg Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,381
-0.71%
|
$30,429
$9.41 P/Share
|
|
Jan 04
2025
|
Jeff Castelli Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,127
-0.71%
|
$28,143
$9.41 P/Share
|
|
Jan 04
2025
|
Bradley L Campbell President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,368
-0.68%
|
$66,312
$9.41 P/Share
|
|
Jan 03
2025
|
David Michael Clark Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,987
-3.62%
|
$107,883
$9.41 P/Share
|
|
Jan 03
2025
|
David Michael Clark Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,228
+17.29%
|
-
|
|
Jan 03
2025
|
Samantha Prout Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,275
-7.87%
|
$74,475
$9.41 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.08M shares |
|---|---|
| Exercise of conversion of derivative security | 137K shares |
| Open market or private sale | 136K shares |
|---|---|
| Payment of exercise price or tax liability | 349K shares |